Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on March 13, 2008

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008
Published online before print March 13, 2008, doi: 10.1161/ATVBAHA.107.157776
A more recent version of this article appeared on May 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Additional Materials
Right arrow All Versions of this Article:
28/5/835    most recent
ATVBAHA.107.157776v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yang, Y.-H.
Right arrow Articles by Xu, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, Y.-H.
Right arrow Articles by Xu, A.

Submitted on October 14, 2007
Accepted on February 27, 2008

Suppression of the Raf/MEK/ERK Signaling Cascade and Inhibition of Angiogenesis by the Carboxyl Terminus of Angiopoietin-Like Protein 4

Ying-Hua Yang ; Yu Wang ; Karen S.L. Lam ; Ming-Hon Yau ; Kenneth K.Y. Cheng ; Jialiang Zhang ; Weidong Zhu ; Donghai Wu ; and Aimin Xu *

From the Departments of Medicine (Y.-H.Y., K.S.L.L., M.-H.Y., K.K.Y.C., J.Z., W.Z., A.X.), Research Center of Heart, Brain, Hormone, and Healthy Aging (Y.-H.Y., Y.W., K.S.L.L., M.-H.Y., K.K.Y.C., J.Z., W.Z., A.X.), and Genome Research Center (Y.W.), and the Department of Pharmacology (A.X.), The University of Hong Kong, and the Guang Zhou Institute of Biomedicine and Health (D.W., A.X.), Chinese Academy of Sciences, China.

* To whom correspondence should be addressed. E-mail: amxu{at}hkucc.hku.hk.

Objectives—Angiopoietin-like protein 4 (Angptl4) is a secreted glycoprotein that has recently been implicated in the regulation of angiogenesis and metastasis. This study aimed to investigate the structural and cellular basis underlying the biological actions of Angptl4.

Methods and Results—Circulating Angptl4 was proteolytically cleaved into NH2-terminal coiled-coil domain (N-Angptl4) and COOH-terminal fibrinogen-like domain (C-Angptl4). Using amino acid sequencing analysis, we identified a major cleavage site between Lys168 and Leu169 and a minor cleavage site between Lys170 and Met171 in mouse Angptl4. C-Angptl4, but not N-Angptl4, potently inhibited both bFGF- and VEGF-induced cell proliferation, migration, and tubule formation in endothelial cells, and prevented neovascularization in mice. Treatment of C-Angptl4 with PNGase F (an N-glycosidase) ablated its N-linked glycosylation, and also significantly attenuated its antiangiogenic activities. C-Angptl4 blocked bFGF-induced activation of ERK1/2 MAP kinase, but had no obvious effect on Akt and P38 MAP kinase. Furthermore, C-Angptl4 abrogated bFGF-induced phosphorylation of Raf-1 and MEK1/2, whereas neither auto-phosphorylation of FGF receptor-1 nor activation of Ras was affected, suggesting that the blockage occurs at the level of Raf-1 activation.

Conclusions—The carboxyl terminus of Angptl4 alone is sufficient to suppress angiogenesis, possibly through inhibiting the Raf/MEK/ERK1/2 MAP kinase pathway in endothelial cells.


Key words: angiogenesis • angiopoietin-like proteins • glycosylation • MAP kinase • neovascularization